About This Test
RAS mutations are commonly found in cancer tissue, causing a permanent activation of the signal transduction pathway downstream of the EGF receptor (EGFR), thus positive signaling for cell growth. Most frequent are KRAS mutations in codons 12,13 in the second (first transcribed) exon. Up to 45% of all colorectal cancer patients exhibit KRAS 12,13 mutations, while another 10-15% may have mutations in KRAS exons 3 and 4 or in the respective regions of the homologous NRAS gene.
Test Parameters (1)
- KRAS & NRAS MUTATION ANALYSIS PANEL
Home Collection
✓ Available
Reports Available In
1 Day
Frequently Asked Questions
Outsourced test are being done from Dr. Lal Path Lab. Charges and reporting time is same as of Dr. Lal Path Labs.
Block should have at least 10% tumor tissue. Physician prescription is mandatory.
KRAS and NRAS are genes that produce proteins involved in the RAS/MAPK signaling pathway, which regulates cell growth, division, and survival. Mutations in these genes can lead to uncontrolled cell proliferation, commonly seen in colorectal cancer (CRC) and other solid tumors. Testing for these mutations helps guide targeted therapy and prognosis.
TAT Policy
The Turnaround Time (TAT) depends on the following factors:
- Registration date and time
- Type of scan or test
- Scan time or sample collection time
In uncommon circumstances, TAT may be delayed due to test complexity or reasons beyond our control. You will be informed of the estimated TAT at the time of registration.
